<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Adocia Sa — News on 6ix</title>
<link>https://6ix.com/company/adocia-sa</link>
<description>Latest news and press releases for Adocia Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 18:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/adocia-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52785beedb30cb6f69cc9.webp</url>
<title>Adocia Sa</title>
<link>https://6ix.com/company/adocia-sa</link>
</image>
<item>
<title>ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-full-year-2025-financial-results-and-provides-a-corporate-and-financial-update-4</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-full-year-2025-financial-results-and-provides-a-corporate-and-financial-update-4</guid>
<pubDate>Tue, 21 Apr 2026 18:30:00 GMT</pubDate>
<description>LYON, France, April 21, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, publishes its annual financial results as of December 31, 2025. The consolidated statements contained herein were approved by Adocia’s board of directors on April 20, 2026. Audit procedures have been completed and the audit report</description>
</item>
<item>
<title>ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-and-vester-finance-sign-a-shareholder-loan-agreement-enabling-adocia-to-extend-its-cash-runway-until-beginning-q2-2027-2</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-and-vester-finance-sign-a-shareholder-loan-agreement-enabling-adocia-to-extend-its-cash-runway-until-beginning-q2-2027-2</guid>
<pubDate>Tue, 21 Apr 2026 17:30:00 GMT</pubDate>
<description>LYON, France, April 21, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the establishment of a shareholder loan agreement with Vester Finance, repayable in new shares, with an option for the Company to repay in cash under certain conditions.</description>
</item>
<item>
<title>ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-reports-fourth-quarter-2025-financial-results-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-reports-fourth-quarter-2025-financial-results-and-provides-a-business-update</guid>
<pubDate>Tue, 24 Feb 2026 17:00:00 GMT</pubDate>
<description>LYON, France, February 24, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the fourth quarter of 2025 and provides a business update.</description>
</item>
<item>
<title>ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-1</guid>
<pubDate>Thu, 22 Jan 2026 17:00:00 GMT</pubDate>
<description>LYON, France, January 22, 2026--Regulatory News: Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31, 2025:</description>
</item>
<item>
<title>ADOCIA Announces its Financial Calendar for 2026</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-its-financial-calendar-for-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-its-financial-calendar-for-2026-1</guid>
<pubDate>Thu, 18 Dec 2025 17:00:00 GMT</pubDate>
<description>LYON, France, December 18, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.</description>
</item>
<item>
<title>ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong™ - and Provides an Update on its BioChaperone® Platform</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-filing-of-patent-for-new-long-acting-peptides-platform-in-diabetes-and-obesity-adoxlongtm-and-provides-an-update-on-its-biochaperoner-platform-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-filing-of-patent-for-new-long-acting-peptides-platform-in-diabetes-and-obesity-adoxlongtm-and-provides-an-update-on-its-biochaperoner-platform-1</guid>
<pubDate>Wed, 12 Nov 2025 06:30:00 GMT</pubDate>
<description>LYON, France, November 12, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announces the submission of a patent for a new long-acting peptide platform, and two feasibility studies using its BioChaperone® technology with two undisclosed pharmaceutical companies.</description>
</item>
<item>
<title>ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-reports-third-quarter-2025-financial-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-reports-third-quarter-2025-financial-results-and-provides-a-business-update-1</guid>
<pubDate>Wed, 15 Oct 2025 16:00:00 GMT</pubDate>
<description>LYON, France, October 15, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the third quarter of 2025 and provides a business update.</description>
</item>
<item>
<title>ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperoner-lispro-thdb0206-injection-in-people-with-t1d-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperoner-lispro-thdb0206-injection-in-people-with-t1d-1</guid>
<pubDate>Wed, 15 Oct 2025 06:45:00 GMT</pubDate>
<description>LYON, France, October 15, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the second Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation.</description>
</item>
<item>
<title>ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-first-half-2025-financial-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-first-half-2025-financial-results-and-provides-a-business-update-1</guid>
<pubDate>Thu, 25 Sep 2025 16:00:00 GMT</pubDate>
<description>LYON, France, September 25, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces today its first half financial results for the six months period ended June 30th, 2025, and provides a business update.</description>
</item>
<item>
<title>ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-oral-presentations-on-adoshellr-and-biochaperoner-at-easd-esb-and-podd-2025-annual-meetings-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-oral-presentations-on-adoshellr-and-biochaperoner-at-easd-esb-and-podd-2025-annual-meetings-1</guid>
<pubDate>Wed, 03 Sep 2025 16:00:00 GMT</pubDate>
<description>LYON, France, September 03, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announces oral presentations highlighting the latest preclinical results obtained on its innovative technological platform AdoShell® at EASD and ESB 2025 annual meetings. Adocia will also present at the next PODD 2025 it</description>
</item>
<item>
<title>ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperoner-lispro-thdb0206-injection-in-people-with-t2d-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperoner-lispro-thdb0206-injection-in-people-with-t2d-1</guid>
<pubDate>Fri, 25 Jul 2025 06:45:00 GMT</pubDate>
<description>LYON, France, July 25, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation.</description>
</item>
<item>
<title>ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-reports-second-quarter-2025-financial-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-reports-second-quarter-2025-financial-results-and-provides-a-business-update-1</guid>
<pubDate>Wed, 23 Jul 2025 16:00:00 GMT</pubDate>
<description>LYON, France, July 23, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2025 and provides a business update.</description>
</item>
<item>
<title>ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to Stem Cell-Derived Islets</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-presentations-at-ada-and-ipita-scientific-conferences-highlight-scalability-and-good-translation-of-adoshellr-from-human-islets-to-stem-cell-derived-islets-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-presentations-at-ada-and-ipita-scientific-conferences-highlight-scalability-and-good-translation-of-adoshellr-from-human-islets-to-stem-cell-derived-islets-1</guid>
<pubDate>Tue, 24 Jun 2025 16:00:00 GMT</pubDate>
<description>LYON, France, June 24, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), today announced the presentation of the latest preclinical data from its innovative AdoShell® technology platform at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to S</description>
</item>
<item>
<title>ADOCIA Confirms its Eligibility for the PEA‑PME Scheme</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-confirms-its-eligibility-for-the-peapme-scheme-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-confirms-its-eligibility-for-the-peapme-scheme-1</guid>
<pubDate>Thu, 22 May 2025 16:00:00 GMT</pubDate>
<description>LYON, France, May 22, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code.</description>
</item>
<item>
<title>ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-11th-2025-in-paris-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-11th-2025-in-paris-1</guid>
<pubDate>Wed, 21 May 2025 16:00:00 GMT</pubDate>
<description>LYON, France, May 21, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 11th, 2025, at 2:00 pm, in the Jones Day’s offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris.</description>
</item>
<item>
<title>ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-reports-first-quarter-2025-financial-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-reports-first-quarter-2025-financial-results-and-provides-a-business-update-1</guid>
<pubDate>Wed, 14 May 2025 16:00:00 GMT</pubDate>
<description>LYON, France, May 14, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2025 and provides a business update.</description>
</item>
<item>
<title>ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes</title>
<link>https://6ix.com/company/adocia-sa/news/adocia-to-present-new-data-on-adoshellr-at-upcoming-scientific-conferences-showcasing-potential-curative-treatment-for-type-1-diabetes-1</link>
<guid isPermaLink="true">https://6ix.com/company/adocia-sa/news/adocia-to-present-new-data-on-adoshellr-at-upcoming-scientific-conferences-showcasing-potential-curative-treatment-for-type-1-diabetes-1</guid>
<pubDate>Mon, 28 Apr 2025 16:00:00 GMT</pubDate>
<description>LYON, France, April 28, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), today announced the latest preclinical data from its innovative AdoShell® technology platform have been selected for presentations at four upcoming scientific conferences.</description>
</item>
</channel>
</rss>